DelveInsight Business Research LLP

DelveInsight’s “Cocaine Use Disorder – Market Insights, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the Cocaine Use Disorder, historical and forecasted epidemiology as well as the Cocaine Use Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Highlights Cocaine Use Disorder Market 

• Key Companies working in the Cocaine Use Disorder market are STALICLA, Embera NeuroTherapeutics, and many others.

• Key Therapies in Cocaine Use Disorder are STP7/mavoglurant and EMB-001 and many others.

• In 2022, the market size of Cocaine Use Disorder was highest in the US among the 7MM, accounting for approximately USD 35.5 million, expected to increase by 2032.

• The market size in the 7MM will increase at a CAGR of 18.1%

Cocaine Use Disorder Overview

Cocaine use disorder (CUD) is a pattern of cocaine use leading to clinically significant impairment or distress. Cocaine is a powerfully addictive stimulant made from coca plant leaves native to South America. Its use is associated with cardiovascular and neurologic effects, and chronic repeated exposure leads to tolerance, adverse psychological and behavioral effects, and complications, including infections, stroke, and seizure.

The use of cocaine increases the levels of the natural chemical messenger called dopamine in the brain; dopamine controls pleasure and movement. In normal instances, the brain releases dopamine in response to possible rewards, such as the smell of good food, then cycles back into the released cell and shuts off the signal between nerve cells. However, in cocaine use, dopamine is prevented from re-cycling, which causes extra amounts to build up between nerve cells. Because of this “flood” of dopamine, normal brain communication is interrupted, causing the high that people get from cocaine.

The sign and symptoms of CUD can be categorized into four groups: mood symptoms, behavioral symptoms, physical symptoms, and psychological symptoms. Some of the CUD symptoms include anxiety, restlessness, extreme talking, increased energy, decreased need to sleep, headaches, severe paranoia, violent mood swings, and a break from reality.

Cocaine Use Disorder Epidemiology Insights

• The total number of 12-month diagnosed prevalent cases of Cocaine Use Disorder in the United States was around 1,152,759 cases in 2022.

• The US contributed to the largest 12-month diagnosed prevalent population of Cocaine Use Disorder, acquiring ~62% of the 7MM in 2022. Whereas EU4 the UK, and Japan accounted for around 33% and 5% of the total population share, respectively, in 2022.

• In the US, males diagnosed with Cocaine Use Disorder are higher in number than females. In 2022, cases of Cocaine Use Disorder among males were approximately 805,548, while there were approximately 347,211 CUD cases among the female population. These numbers are expected to rise during the study period.

• According to DelveInsight estimates, in EU4 and the UK, the diagnosed prevalence of Cocaine Use Disorder is highest in the =35 age group, while 12–17 years has the least cases. In EU4 and the UK, the =35 age group accounted for the highest number of diagnosed CUD cases, 312,774, followed by 281,730 cases in 18–34 years and 20,225 cases in 12–17 years in 2022, which is projected to increase during the forecast period.

• According to DelveInsight estimates, in Japan, the diagnosed prevalence of mild cases of Cocaine Use Disorder is more than the moderate-severe cases. In 2022, there were approximately 61,342 mild, and 40,725 moderate-severe cases of Cocaine Use Disorder in Japan, projected to decrease during the forecast period.

Click here to learn more about the Cocaine Use Disorder Market Landscape

The Report Covers the Cocaine Use Disorder Epidemiology Segmented by:

• Cocaine Use Disorder prevalent cases  

• Cocaine Use Disorder incident cases 

• Cocaine Use Disorder  treatment cases 

• Cocaine Use Disorder diagnosed cases 

Cocaine Use Disorder Market Outlook 

Cocaine is among the major illicit stimulants used worldwide. There is an increased risk of dependence with heavier use and when cocaine is smoked or injected. Additionally, cocaine abuse is associated with significant mortality and morbidity with cardiovascular and neurologic effects, and chronic repeated exposure leads to tolerance, adverse psychological and behavioral effects, and complications, including infections, stroke, and seizure. However, no medication has yet been approved to treat Cocaine Use Disorder; psychosocial treatment is currently the standard.

Several psychological treatments, including group counseling, individual drug counseling, cognitive behavioral therapy, and contingency management, are effective; however, many patients still do not respond to these treatments which are associated with high dropout rates. Despite decades of efforts, Cocaine Use Disorder has not responded well to pharmacotherapeutic interventions. Nevertheless, a significant understanding of neurobiology has led to the discovery of potential medications like dopamine agonists, including long-acting amphetamine, modafinil, and ?-aminobutyric acid (GABA)/glutamatergic medications, including topiramate. A few combination medications, such as topiramate and mixed amphetamine salts, also appear promising. The current market has been segmented into different commonly used therapeutic classes based on the prevailing treatment pattern across the 7MM, which presents minor variations in the overall prescription pattern. Disulfiram, topiramate, and modafinil are the major drugs covered in the forecast model.

Key Companies Working in the Cocaine Use Disorder Market

• STALICLA

• Embera NeuroTherapeutics

And many others 

 Cocaine Use Disorder Therapies Covered and Analyzed in the Report

• STP7

• EMB-001

And many others 

Learn more about the Key Companies and Emerging Therapies in the Cocaine Use Disorder  Market

 Table of Contents 

1.  Key Insights 

2.  Cocaine Use Disorder Introduction 

3.  Executive Summary of Cocaine Use Disorder             

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Cocaine Use Disorder Emerging Therapies

7.  Cocaine Use Disorder Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Cocaine Use Disorder Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services